PDF(Pubmed)
Abstract：
UNASSIGNED: Orforglipron is a novel once-daily oral non-peptide glucagon-like peptide-1 receptor agonist with several recently published randomized controlled trials (RCTs) evaluating its role in diabetes and obesity. No meta-analysis has analyzed the efficacy and safety of orforglipron; this meta-analysis aimed to address this knowledge gap.
UNASSIGNED: A systematic search was conducted in electronic databases to identify RCTs that included individuals with obesity who were administered orforglipron and compared to either a placebo or an active comparator. The primary outcome of interest was the percent change in body weight.
UNASSIGNED: From 12 initially screened articles, data from three RCTs involving 774 people were analyzed with a follow-up duration of up to 36 weeks. Compared to placebo, patients receiving orforglipron 12 mg/day (mean difference (MD), MD -5.48%, 95% CI [-7.64, -3.33], p < 0.01), 24 mg/day (MD -8.51%, 95% confidence interval (CI) [-9.88, -7.14], p < 0.01), 36 mg/day (MD -8.84%, 95% CI [-11.68, -6.00], p < 0.01) and 45 mg/day (MD -8.24%, 95% CI [-12.84, -3.63], p < 0.01) had a significantly greater percent reduction in body weight. The percentage of patients being able to achieve >15% weight loss from baseline was significantly higher with orforglipron 24 mg/day [Odds ratio (OR) 21.90 (95% CI [4.06, 118.15], p = 0.0003), 36 mg/day (OR 17.43, 95% CI [3.18, 95.66], p = 0.001) and 45 mg/day (OR 23.17, 95% CI [4.37, 123.03], p = 0.0002). Total but not severe adverse events were significantly higher with all the doses of orforglipron compared to placebo, with the hazard ratios being higher with higher doses. Gastrointestinal side-effects were predominant side effects, being dose-dependent, with nausea, vomiting, constipation, and gastroesophageal reflux being the predominant ones.
UNASSIGNED: Orforglipron at 24-45 mg/day doses is an effective weight loss medication. The efficacy versus side effect profile suggests that 24-36 mg/day is the most optimal dose for orforglipron as an anti-obesity medicine.
UNASSIGNED: A systematic search was conducted in electronic databases to identify RCTs that included individuals with obesity who were administered orforglipron and compared to either a placebo or an active comparator. The primary outcome of interest was the percent change in body weight.
UNASSIGNED: From 12 initially screened articles, data from three RCTs involving 774 people were analyzed with a follow-up duration of up to 36 weeks. Compared to placebo, patients receiving orforglipron 12 mg/day (mean difference (MD), MD -5.48%, 95% CI [-7.64, -3.33], p < 0.01), 24 mg/day (MD -8.51%, 95% confidence interval (CI) [-9.88, -7.14], p < 0.01), 36 mg/day (MD -8.84%, 95% CI [-11.68, -6.00], p < 0.01) and 45 mg/day (MD -8.24%, 95% CI [-12.84, -3.63], p < 0.01) had a significantly greater percent reduction in body weight. The percentage of patients being able to achieve >15% weight loss from baseline was significantly higher with orforglipron 24 mg/day [Odds ratio (OR) 21.90 (95% CI [4.06, 118.15], p = 0.0003), 36 mg/day (OR 17.43, 95% CI [3.18, 95.66], p = 0.001) and 45 mg/day (OR 23.17, 95% CI [4.37, 123.03], p = 0.0002). Total but not severe adverse events were significantly higher with all the doses of orforglipron compared to placebo, with the hazard ratios being higher with higher doses. Gastrointestinal side-effects were predominant side effects, being dose-dependent, with nausea, vomiting, constipation, and gastroesophageal reflux being the predominant ones.
UNASSIGNED: Orforglipron at 24-45 mg/day doses is an effective weight loss medication. The efficacy versus side effect profile suggests that 24-36 mg/day is the most optimal dose for orforglipron as an anti-obesity medicine.
摘要：
■Orforglipron是一种新型的每日一次口服非肽胰高血糖素样肽-1受体激动剂，最近发表了几项随机对照试验（RCT），评估了其在糖尿病和肥胖症中的作用。没有荟萃分析分析了orforglipron的疗效和安全性；这项荟萃分析旨在解决这一知识差距。
■在电子数据库中进行了系统搜索，以确定包括肥胖个体的RCT，这些个体接受了或给予了glipron，并与安慰剂或活性比较剂进行了比较。感兴趣的主要结果是体重的百分比变化。
■从最初筛选的12篇文章中，我们分析了3个RCT的数据,包括774人,随访时间长达36周.与安慰剂相比，接受orforforglipron12毫克/天的患者(平均差(MD)，MD-5.48%,95%CI[-7.64，-3.33]，p<0.01),24毫克/天（MD-8.51%，95%置信区间(CI)[-9.88，-7.14]，p<0.01),36毫克/天（MD-8.84%，95%CI[-11.68，-6.00]，p<0.01）和45毫克/天（MD-8.24%，95%CI[-12.84，-3.63]，p<0.01）的体重减轻百分比明显更大。与基线相比能够实现>15%体重减轻的患者百分比显著高于24mg/天的orforgliproon[赔率比(OR)21.90(95%CI[4.06,118.15],p=0.0003),36毫克/天（OR17.43，95%CI[3.18，95.66]，p=0.001）和45mg/天（OR23.17，95%CI[4.37，123.03]，p=0.0002)。与安慰剂相比，所有剂量的orfroglipron的总但非严重不良事件均显着较高，剂量越高，危险比就越高。胃肠道副作用是主要的副作用，是剂量依赖性的，恶心，呕吐,便秘,胃食管反流是主要的。
■24-45毫克/天剂量的Orforglipron是一种有效的减肥药物。疗效与副作用的关系表明，24-36毫克/天是orforglipron作为抗肥胖药物的最佳剂量。
■在电子数据库中进行了系统搜索，以确定包括肥胖个体的RCT，这些个体接受了或给予了glipron，并与安慰剂或活性比较剂进行了比较。感兴趣的主要结果是体重的百分比变化。
■从最初筛选的12篇文章中，我们分析了3个RCT的数据,包括774人,随访时间长达36周.与安慰剂相比，接受orforforglipron12毫克/天的患者(平均差(MD)，MD-5.48%,95%CI[-7.64，-3.33]，p<0.01),24毫克/天（MD-8.51%，95%置信区间(CI)[-9.88，-7.14]，p<0.01),36毫克/天（MD-8.84%，95%CI[-11.68，-6.00]，p<0.01）和45毫克/天（MD-8.24%，95%CI[-12.84，-3.63]，p<0.01）的体重减轻百分比明显更大。与基线相比能够实现>15%体重减轻的患者百分比显著高于24mg/天的orforgliproon[赔率比(OR)21.90(95%CI[4.06,118.15],p=0.0003),36毫克/天（OR17.43，95%CI[3.18，95.66]，p=0.001）和45mg/天（OR23.17，95%CI[4.37，123.03]，p=0.0002)。与安慰剂相比，所有剂量的orfroglipron的总但非严重不良事件均显着较高，剂量越高，危险比就越高。胃肠道副作用是主要的副作用，是剂量依赖性的，恶心，呕吐,便秘,胃食管反流是主要的。
■24-45毫克/天剂量的Orforglipron是一种有效的减肥药物。疗效与副作用的关系表明，24-36毫克/天是orforglipron作为抗肥胖药物的最佳剂量。
